Lilly escalates its fight against black market weight-loss shots

Eli Lilly is intensifying its battle against the black market trade of its experimental weight-loss drug retatrutide. The pharmaceutical company has filed several lawsuits against US businesses, primarily in Texas, that sell the unauthorized version of the shot. Lilly is also urging regulators to take stronger measures to curb the illicit market, which has become a significant public health crisis.

Dr. Max Denning, Lilly's associate vice president for global patient safety, likened the struggle to a "whack-a-mole" game, as these counterfeit drugs are often manufactured by unregulated foreign producers. The FDA has issued warning letters to at least 16 companies suspected of selling retatrutide, but many continue to offer illegal versions.

Lilly has reported over 14,000 websites, advertisements, social media posts, and product listings in more than 100 countries, but some companies persist in spreading misleading content to vulnerable consumers. The hype surrounding retatrutide has escalated due to promising mid-stage study results, with the drug potentially generating over $5.4 billion in annual sales for Lilly by 2030.

However, the black market poses a substantial risk, as any safety concerns from counterfeit versions could tarnish the drug's reputation. Lilly has been collaborating with law enforcement in various countries, including the UK, Brazil, New Zealand, Saudi Arabia, and Hong Kong, to tackle this issue.